초록 ▼

A novel method of treating Kaposi's sarcoma (KS) in patients, by administration of an effective amount of VEGF antagonist/s. VEGF antagonists are capable of inhibiting the growth of KS cells in culture by inhibiting the production of VEGF, or by interfering with the binding of VEGF to its cognate re

A novel method of treating Kaposi's sarcoma (KS) in patients, by administration of an effective amount of VEGF antagonist/s. VEGF antagonists are capable of inhibiting the growth of KS cells in culture by inhibiting the production of VEGF, or by interfering with the binding of VEGF to its cognate receptors or interfere with the biological effects of VEGF. The VEGF antagonist may be administered to KS patients topically, orally, or parentally. Other VEGF antagonist such as VEGF antibodies, VEGF receptor antibodies, soluble forms of VEGF receptors that bind VEGF away from the cells, or agents that inhibit the signal of VEGF into the cell such as protein kinase inhibitors etc. can also be used The novel antisense oligonucleotides (Veglin-1 and Veglin-3) may also be used to inhibit VEGF and thus new blood vessel formation in diseases such as tumors, proliferative retinopathy, or collagen vascular diseases such as rheumatoid arthritis, and skin diseases such as pemphigus and psoriasis. The KS cell lines also allow-the screening of other VEGF inhibitors.

대표청구항

[ What is claimed:] [1.]1. A composition, which comprises one or more VEGF antisense oligonucleotides and wherein the one or more antisense oligonucleotides are selected from the group consisting of 5'-AGA CAG CAG AAA GTT CAT GGT-3' (SEQ ID NO 1) or 5'-TGG CTT GAA GAT GTA CTC GAT-3' (SEQ ID NO. 2).

[ What is claimed:] [1.]1. A composition, which comprises one or more VEGF antisense oligonucleotides and wherein the one or more antisense oligonucleotides are selected from the group consisting of 5'-AGA CAG CAG AAA GTT CAT GGT-3' (SEQ ID NO 1) or 5'-TGG CTT GAA GAT GTA CTC GAT-3' (SEQ ID NO. 2).